1. Home
  2. WWR vs NSPR Comparison

WWR vs NSPR Comparison

Compare WWR & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

WWR

Westwater Resources Inc.

HOLD

Current Price

$0.51

Market Cap

82.3M

ML Signal

HOLD

Logo InspireMD Inc.

NSPR

InspireMD Inc.

HOLD

Current Price

$0.72

Market Cap

72.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WWR
NSPR
Founded
1977
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Mining
Medical/Dental Instruments
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
82.3M
72.1M
IPO Year
2006
2009

Fundamental Metrics

Financial Performance
Metric
WWR
NSPR
Price
$0.51
$0.72
Analyst Decision
Strong Buy
Buy
Analyst Count
3
1
Target Price
$1.92
$4.00
AVG Volume (30 Days)
936.5K
164.0K
Earning Date
05-13-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,310,000.00
Revenue This Year
N/A
$57.98
Revenue Next Year
N/A
$95.41
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.47
$0.69
52 Week High
$3.75
$2.93

Technical Indicators

Market Signals
Indicator
WWR
NSPR
Relative Strength Index (RSI) 39.62 30.58
Support Level $0.47 N/A
Resistance Level $0.72 $1.04
Average True Range (ATR) 0.03 0.09
MACD 0.00 0.00
Stochastic Oscillator 28.58 9.15

Price Performance

Historical Comparison
WWR
NSPR

About WWR Westwater Resources Inc.

Westwater Resources Inc is an energy technology company focused on developing battery-grade natural graphite materials through a vertically integrated, mine-to-market strategy anchored by its two primary projects in Coosa County, Alabama: the Kellyton Graphite Plant and the Coosa Graphite Deposit. Westwater also holds mineral rights to explore and mine the Coosa Graphite Deposit, which Westwater anticipates will eventually provide natural graphite flake concentrate as feedstock to the Kellyton Graphite Plant.

About NSPR InspireMD Inc.

InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.

Share on Social Networks: